Answer choices A, C, and E:
For those individuals with Wolff-Parkinson-White syndrome and suffering from symptomatic arrhythmias, in which either the patient refuses radiofrequency catheter ablation of their accessory pathway or are not candidates, then medical management with pharmacological therapies are an option.
Oral flecainide, propafenone, and amiodarone can be used as a means to prevent future life threatening arrhythmias and to slow the ventricular response rate. However, the optimal selection of the antiarrhythmic agent should be chosen based off of the type of accessory pathway present, underlying comorbid illnesses, and side effects, and thus will vary.
Answer choice B: Percutaneous coronary intervention would not be indicated given that this patient is not having an acute ST segment myocardial infarction.
This one question is working your brain and pulling it in many different directions...much more so than passively listening to lectures.
If you are interested in more like this, then I invite you to invest in our all new Medgeeks question bank.
This has been a long time in the making and we know you’re going to love what we have in store.